Ozmosi | Eribulin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Eribulin

Alternative Names: eribulin, e7389, halaven
Clinical Status: Inactive
Latest Update: 2026-03-10
Latest Update Note: Clinical Trial Update

Product Description

Eribulin injection is used to treat metastatic (cancer that has already spread to other parts of the body) breast cancer in patients who have already received other types of cancer medicines. Eribulin injection is also used to treat metastatic liposarcoma or liposarcoma that cannot be removed with surgery in patients who have received other types of cancer medicines.

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location:
Company Founding Year: 1941
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eribulin

Countries in Clinic: Australia, Canada, China, France, Germany, Israel, Italy, Japan, South Korea, Spain, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 26

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Breast Cancer|Male Breast Cancer

Phase 2: Alopecia|Brain Cancer|Carcinosarcoma|Epithelioid Hemangioendothelioma|Esophageal Cancer|Gastrointestinal Cancer|Hemangiopericytoma|Hemangiosarcoma|Histiocytoma, Malignant Fibrous|Leiomyosarcoma|Liposarcoma|Liver Cancer|Mixed Tumor, Mullerian|Oncology Solid Tumor Unspecified|Ovarian Cancer|Small Cell Lung Cancer|Solitary Fibrous Tumors|Triple Negative Breast Cancer

Phase 1: Adenoid Cystic Carcinoma|Esophageal Cyst|Lymphoma|Peritoneal Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06957431

NCT06957431

P1

Recruiting

Liposarcoma|Leiomyosarcoma

2028-11-30

50%

2025-10-28

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status

NCT03361436

STUDY00017190

P1

Active, not recruiting

Peritoneal Cancer|Liposarcoma

2023-02-14

12%

2023-09-15

2016-001894-34

BOLD 113

P1

Active, not recruiting

Lymphoma

2020-03-02

2025-06-29

Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

NCT03207672

E7389-J081-114

P1

Active, not recruiting

Breast Cancer|Esophageal Cancer|Esophageal Cyst|Small Cell Lung Cancer|Gastrointestinal Cancer|Adenoid Cystic Carcinoma

2018-07-19

50%

2024-03-02

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

2025-521966-91-00

PHP-MBC-202

P2

Not yet recruiting

Liver Cancer|Breast Cancer

2028-12-26

NCT04078295

E7389-J081-120

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2027-03-31

12%

2026-02-12

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

2024-512963-30-00

MEDOPP437

P2

Recruiting

Triple Negative Breast Cancer

2026-12-30

2025-05-02

Treatments

NCT04986579

NCT04986579

P2

Recruiting

Alopecia|Breast Cancer

2026-06-01

75%

2024-06-28

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05810870

SABINA

P2

Active, not recruiting

Breast Cancer

2026-04-01

12%

2026-03-11

NCT05619913

EPOCH

P2

Recruiting

Carcinosarcoma|Mixed Tumor, Mullerian|Ovarian Cancer

2025-03-01

12%

2025-02-05

NCT03840772

ERASING

P2

Completed

Hemangiopericytoma|Solitary Fibrous Tumors

2024-09-18

42%

2024-09-21

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT03899805

NCT03899805

P2

Completed

Histiocytoma, Malignant Fibrous|Leiomyosarcoma|Liposarcoma

2024-07-16

12%

2025-08-29

Primary Endpoints

NCT03331250

NCT03331250

P2

Active, not recruiting

Epithelioid Hemangioendothelioma|Hemangiosarcoma

2023-07-21

12%

2024-11-09

Primary Completion Date|Primary Endpoints|Treatments

2013-001269-18

DETECT - IV

P2

Completed

Triple Negative Breast Cancer|Male Breast Cancer

2023-06-17

2022-03-13

Treatments

2018-001027-40

ERIBRAIN

P2

Completed

Brain Cancer|Breast Cancer

2023-03-11

50%

2025-05-06

Treatments|Trial Status

NCT03424005

Morpheus-panBC

P2

Recruiting

Breast Cancer

2030-09-30

12%

2025-11-29

NCT05458674

02AB21-TucErBit

P2

Recruiting

Breast Cancer

2027-06-01

12%

2025-01-14

Primary Endpoints

2022-001398-30

MEN1611 IN METAPLASIC BREAST CANCER

P2

Active, not recruiting

Breast Cancer

2026-04-20

12%

2020-004909-32

2020-004909-32

P2

Completed

Breast Cancer

2024-10-01

2025-05-06

Primary Completion Date|Study Completion Date|Treatments|Trial Status

2017-004652-35

Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Br

P2

Completed

Breast Cancer

2024-08-30

2025-05-06

JapicCTI-194960

JapicCTI-194960

P2

Active

Small Cell Lung Cancer|Esophageal Cancer|Gastrointestinal Cancer

2022-08-31

2016-004513-27

KELLY study (KEytruda and EribuLin in Luminal breast cancer)

P2

Active, not recruiting

Breast Cancer

2019-08-31

2022-03-13

Treatments

NCT07173751

ROSETTA Breast-01

P3

Recruiting

Breast Cancer

2029-12-01

73%

2025-11-15

NCT03264547

EMERALD

P3

Completed

Breast Cancer

2024-12-31

2025-09-30

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

CTR20130252

CTR20130252

P3

Active, not recruiting

Male Breast Cancer

2018-09-30

2025-04-29

Patient Enrollment|Treatments